

Barcelona, April 5th 2019

SIGNIFICANT EVENT

Almirall: to receive \$65 MM sales-related milestones from the agreement with AstraZeneca

In accordance with article 227 of the Consolidated Text of the Spanish Securities Markets Law approved by the Royal Legislative Decree 4/2015 from 23 October, Almirall, S.A. ("Almirall") hereby notifies the Spanish National Securities Market Commission of the following:

We were notified by our partner AstraZeneca of a sales related payment achievement associated with the agreement effective on 1st November 2014, amended April 2019, and related to the aclidinium bromide franchise (Bronchodilator treatment to relieve the symptoms of chronic obstructive pulmonary disease, COPD). This represents an amount of \$65 MM: \$35 MM will be cash in on 30th April 2019 and the remaining \$30 MM on 31st March 2020.

We remain positive about this collaboration and associated potential future milestones.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations & Corporate Comms. Department
investors@almirall.com